Article
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Oncotarget - 11 Oct 2016
Villaflor Victoria, Won Brian, Nagy Rebecca, Banks Kimberly, Lanman Richard B, Talasaz AmirAli, Salgia Ravi
Abstract excerpt
INTRODUCTION: The potential of oncogene-driven targeted therapy is perhaps most fully realized in non-small cell lung cancer (NSCLC), given the number of genomic targets and approved matched therapies. However, invasive tissue biopsy at the time of each disease progression may not be possible and is associated with high morbidity and cost. Use of newly available "liquid biopsies" can circumvent these issues....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.